Evidence map›Paper›PMID 31736366›Full record

ArticleDrug delivery2019

Transdermal delivery of fluvastatin sodium

Shahira F El Menshawe, Mohamed M Nafady, Heba M Aboud, Rasha M Kharshoum, Asmaa Mohammed M Hussein Elkelawy, Doaa S Hamad

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Nasal In-Situ Gels of BrijAAPS PharmSciTech · 2025
    Article
  6. Stearyl amine tailored spanlastics embedded within tetronicDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Article
  7. Article
  8. Article
  9. Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Optimization of Phloretin-loaded Nanospanlastics for Targeting ofCurrent pharmaceutical biotechnology · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shahira F El MenshaweDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Mohamed M NafadyDepartment of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
Heba M AboudDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Rasha M KharshoumDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Asmaa Mohammed M Hussein ElkelawyDepartment of Pharmacology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Doaa S HamadDepartment of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
Beni-Suef University · EGNahda University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to encapsulate fluvastatin sodium (FVS), a member of the statins family possessing pleiotropic effects in rheumatoid arthritis (RA), into spanlastic nanovesicles (SNVs) for transdermal delivery. This novel delivery could surmount FVS associated oral encumbrances such as apparent first-pass effect, poor bioavailability and short elimination half-life, hence, accomplishing platform for management of RA. To consummate this objective, FVS-loaded SNVs were elaborated by thin film hydration method, utilizing either Span 60 or Span 80, together with Tween 80 or Brij 35 as an edge activator according to full factorial design (2

Indexed as

Administration, CutaneousAnimalsArthritis, ExperimentalArthritis, RheumatoidBiological AvailabilityDrug CarriersDrug Delivery SystemsFemaleFluvastatinFreund's Adjuvantp38 Mitogen-Activated Protein KinasesParticle SizePermeabilityRatsRats, WistarSignal TransductionDrug CarriersFluvastatinFreund's Adjuvantp38 Mitogen-Activated Protein KinasesFluvastatin sodiump38 MAPKrheumatoid arthritisspanlastic nanovesiclestransdermal delivery

Identifiers

PMID31736366
PMCPMC6882467
OpenAlexW2986104088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.